Immunome, Inc.
IMNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $4 | $3 | $3 |
| % Growth | -100% | 37.2% | 6.9% | – |
| Cost of Goods Sold | $49 | $1 | $0 | $0 |
| Gross Profit | -$49 | $3 | $3 | $3 |
| % Margin | – | 82.1% | 100% | 100% |
| R&D Expenses | $49 | $40 | $37 | $48 |
| G&A Expenses | $11 | $10 | $11 | $10 |
| SG&A Expenses | $11 | $10 | $11 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$49 | -$1 | $0 | $27 |
| Operating Expenses | $11 | $50 | $48 | $86 |
| Operating Income | -$60 | -$46 | -$45 | -$83 |
| % Margin | – | -1,157.6% | -1,525.5% | -3,030.3% |
| Other Income/Exp. Net | $3 | $3 | $3 | $3 |
| Pre-Tax Income | -$57 | -$43 | -$42 | -$80 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$57 | -$43 | -$42 | -$80 |
| % Margin | – | -1,080.9% | -1,423.1% | -2,930.9% |
| EPS | -0.65 | -0.5 | -0.52 | -1.28 |
| % Growth | -30% | 3.8% | 59.4% | – |
| EPS Diluted | -0.65 | -0.5 | -0.52 | -1.28 |
| Weighted Avg Shares Out | 88 | 87 | 79 | 63 |
| Weighted Avg Shares Out Dil | 88 | 87 | 79 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$57 | -$46 | -$44 | -$55 |
| % Margin | – | -1,139.7% | -1,500.7% | -2,008.9% |